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Edited by Lev KisselevAbstract Cyclin D3 is found to play a crucial role not only in
progression through the G1 phase as a regulatory subunit of
cyclin-dependent kinase 4 (CDK 4) and CDK 6, but also in many
other aspects such as cell cycle, cell diﬀerentiation, transcrip-
tional regulation and apoptosis. In this work, we screened a
human fetal liver cDNA library using human cyclin D3 as bait
and identiﬁed human eukaryotic initiation factor 3 p28 protein
(eIF3k) as a partner of cyclin D3. The association of cyclin D3
with eIF3k was further conﬁrmed by in vitro binding assay, in
vivo coimmunoprecipitation, and confocal microscopic analysis.
We found that cyclin D3 speciﬁcally interacted with eIF3k
through its C-terminal domain. Immunoﬂuorescence experiments
showed that eIF3k distributed both in nucleus and cytoplasm and
colocalized with cyclin D3. In addition, the cellular translation
activity in HeLa cells was upregulated by cyclin D3 overexpres-
sion and the mRNA levels are constant. These data provide a
new clue to our understanding of the cellular function of cyclin
D3.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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initiation1. Introduction
As cells enter the cell cycle from quiescence, genes encoding
D-type cyclins get activated at the beginning of the G1 phase
[1]. The expression of cyclin D is largely dependent on extra-
cellular signals and signaling cascades, so that D-type cyclins
represent a fundamental link between mitogen, nutrient stim-
ulation and the cell cycle machinery [2].
Among D-type cyclins, mouse cyclin D1 was ﬁrst charac-
terized and then cyclin D2 and cyclin D3 were discovered [3–5].
Compared with cyclin D1 and cyclin D2, little is known about
the function of cyclin D3. Most of the studies of cyclin D3* Corresponding author. Fax: +86-21-64164489.
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RT-PCR, reverse transcription-polymerase chain reaction; ECL,
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phosphate-buﬀered saline; SDS–PAGE, sodium dodecyl sulfate–poly-
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doi:10.1016/j.febslet.2004.07.071focus on its association with cyclin-dependent kinase 4 (CDK
4) and CDK 6 to drive cells through a G1 restriction point.
The studies of our group have shown that cyclin D3 is found
not only to play a crucial role in progression through the G1
phase as a regulatory subunit of CDK 4 and CDK 6, but also
to interact with CDK 11p58, a G2/M CDK, in G2/M phase
instead of G1/S phase as a partner of CDK 11p58, and the el-
evated expression of cyclin D3 aﬀects CDK 11p58 cellular
distribution, resulting in enhanced kinase activity of CDK
11p58 [6]. The ﬁrst observation regarding a new potential of D-
type cyclins was reported when it was shown that cyclin D2 or
cyclin D3 inhibit 32D myeloid cells to undergo neutrophil
diﬀerentiation in response to granulocyte colony-stimulating
factor [7], suggesting that cyclin D3 is able to modulate dif-
ferentiation program. In addition, cyclin D3 is found to be
involved in a complexity of networks of interactions and play
new cdk-independent roles. Cyclin D3 can interact with dif-
ferent kinds of transcription factors. Like cyclin D1, cyclin D3
could form a speciﬁc complex with the estrogen receptor (ER)
and activate ER-mediated transcription activity in a CDK 4
and ligand independent manner and show a less pronounced
eﬀect than cyclin D1 on ER [8,9]. Cyclin D3 is also a cofactor
of retinoic acid receptors, modulating their activity in the
presence of cellular retinoic acid-binding protein II [10].
Through direct binding, cyclin D3 could inhibit the growth-
restraining capacity of the DMP1 [11]. These ﬁndings suggest
that cyclin D3 may play an important role in the regulation of
transcription. Surprisingly, cyclin D3 is found to activate
Caspase 2 [12] and regulate apoptosis induced by T cell re-
ceptor activation in leukemic T cell lines [13], which suggests
that a physical interaction between cyclin D3 and Caspase 2
connects the genetic networks that govern cell-cycle progres-
sion with those that govern cell death [12].
Altogether, cyclin D3 represents a central link between cell
cycle progression, cell diﬀerentiation, transcriptional regulation
and apoptosis. Since identiﬁcation of cell-speciﬁc partners of
cyclin D3 might help us to understand the genetic networks in
which cyclin D3 might be involved more thoroughly and sys-
tematically, we performed a yeast two-hybrid screen of a human
fetal liver cDNA library using human cyclin D3 as bait and
subsequently identiﬁed human eukaryotic initiation factor 3
p28 protein (eIF3k) as a partner of cyclin D3.
Mammalian translation initiation factor 3 (eIF3) is the most
complex and least understood of the protein synthesis initia-
tion factors, containing at least 12 subunits with an apparent
aggregate mass of approximately 700 kDa [14]. eIF3 binds toation of European Biochemical Societies.
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tRNAi and mRNA, and interacts with several other initiation
factors to form the 43S initiation complex [15]. Twelve non-
identical subunits have been identiﬁed in mammalian eIF3 and
their cDNAs have been cloned and characterized: a (p170) [16],
b (p116) [17], c (p110) [18], d (p66) [19], e (p48) [20], f (p47)
[19], g (p44) [21], h (p40) [19], i (p36) [18], j (p35) [21], k (p28)
[14] and l (p69) [22]. Since it was reported that eIF3k mRNA is
highly expressed in the brain, testis and kidney tissues, espe-
cially in HeLa and Jurkat cell lines [14], we adopted HeLa cells
to further our study on eIF3k in this work.
Here, we report that eIF3k is a new interaction partner of
cyclin D3, which is the unique one among D-type cyclins that
binds with eIF3k through its C-terminal domain. Its distri-
bution is consistent with that of cyclin D3 by ﬂuorescence
microscopy. The whole cellular translation activity was ap-
parently enhanced by cyclin D3 expression in a dose-depen-
dent manner.2. Materials and methods
2.1. Cell lines and reagents
HeLa cells were obtained from the Institute of Cell Biology, Aca-
demic Sinica. MATCHMAKER LexA two-hybrid system and human
fetal liver MATCHMAKER LexA cDNA library were products of
CLONTECH (Palo Alto, CA). Protein-G-agarose, glutathione
Sepharose beads, and the mouse monoclonal anti-Myc antibody were
purchased from Roche Company. The mouse monoclonal anti-cyclin
D1, D2, and D3 antibodies were bought from PharMingen. The
rabbit Myc-tag polyclonal antibody was purchased from Cell Sig-
naling. The ﬂuorescein goat anti-mouse IgG and mouse monoclonal
anti-actin antibody were purchased from Oncogene. The goat anti-
rabbit IgG-R was purchased from Santa Cruz Biotechnology. Leu-
peptin, aprotinin and phenylmethylsulfonyl ﬂuoride (PMSF) were
purchased from Sigma Chemical Co., the goat anti-mouse-horserad-
ish peroxidase (HRP) secondary antibody, [35S]methionine, hybond
polyvinylidene diﬂuoride (PVDF) membrane, and the enhanced
chemiluminescence (ECL) assay kit were purchased from Amersham
Pharmacia Biotech. The TNT T7 coupled reticulocyte lysate system
and the dual-luciferase reporter assay system were purchased from
Promega. The LipofectAMINETM and Trizol reagents were bought
from Invitrogen. Real-time reverse transcription-polymerase chain
reaction (RT-PCR) kit was purchased from TaKaRa. The nuclear
extract kit was purchased from Activemotif. Other reagents were
commercially available in China.
2.2. Yeast two-hybrid assays
MATCHMAKER LexA two-hybrid system was used to perform
yeast two-hybrid screening according to the manufacturer’s instruc-
tions. The full-length cyclin D3 was cloned in-frame into LexA coding
sequence to generate bait plasmid, pLexA-cyclin D3. A human fetal
liver cDNA library in the pB42AD plasmid (CLONTECH) was
screened for proteins that interact with cyclin D3 using EGY48 yeast
strain. The transformed yeast was grown on plates lacking both his-
tidine to select the bait plasmid and tryptophan to select the prey
plasmid, respectively. The individual cDNA of interest was puriﬁed
from the positive clones and re-transformed into yeast to conﬁrm its
speciﬁc interaction with cyclin D3.
2.3. Cell culture, transient transfection and cell fractionation
HeLa cells were cultured with DMEM supplemented with 10% FBS,
1% penicillin/streptomycin at 37 C in 5% CO2. Cells were plated at
70% conﬂuence in 60 mm tissue culture dishes or six-well plates and the
following day were transfected with relevant plasmids using Lipofec-
tAMINETM transfection reagent according to the manufacturer’s
recommendations. After 48 h, the cells were harvested for further
analysis. The cytoplasmic and nuclear fractions from HeLa cells were
collected using the nuclear extract kit under the manufacturer’s
instructions.2.4. Western blot analysis
Western blot experiments were used to measure certain proteins.
Brieﬂy, the cells were lysed in lysis buﬀer (120 mM Tris (pH 7.4), 135
mM NaCl, 1 mM EDTA, 1% NP40, 0.1% SDS, 1 mM Na3VO4, 1 mM
aprotinin, and 1 mM PMSF). An equivalent amount of protein from
each sample was electrophoresed by 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) and then transferred
to a PVDF membrane. After blocking with phosphate-buﬀered saline
(PBS) containing 5% non-fat milk and 0.1% Tween 20 overnight, the
membrane was incubated with primary antibody at 4 C overnight.
After washing with PBS containing 0.1% Tween 20 three times, each
for 5 min, the membrane was then incubated with HRP-labeled sec-
ondary antibody for another 2 h at room temperature (RT). The
membrane was then developed using the ECL detection systems.
2.5. Plasmid construction
The full-length cyclin D3 (GenBank Accession No. NM_001760)
isolated from the original fetal cDNA was cloned into the EcoRI/XhoI
site of pLexA in-frame with the DNA binding domain of LexA. The
eukaryotic expression vectors pcDNA3.0-GST-CDK 4, pcDNA3.0-
cyclin D1, D2, and D3, pcDNA3.0-GST have previously been de-
scribed [6]. The full-length eIF3k from the original fetal cDNA was
cloned into pLexA vector by EcoRI and XhoI. The deﬁcient mutants of
cyclin D3 were designated as N1 (1–88 aa), N (1–153 aa), and C (154–
292 aa), and performed by PCR using pLexA-cyclin D3 as template.
N1 was generated from primer 1 (50-gCGAATTCATGGAG-
CTGCTGTGTTGC-30) and primer 2 (50-TTTCTCGAGCTACAGG-
TAGCGATCCAGGTAG-30), N from primer 1 and primer 3
(50-ATGCTCGAGCTAAGCAGCCAGGTCCCACTTG-30), and C
from primer 4 (50-GGGAATTCATGGCTGTGATTGCACATGAT-
TTC-30) and primer 5 (50-GATCTCGAGCTACAGGTGTATGGC-
TG-30). The EcoRI site underlined in the forward primers and the XhoI
site underlined in the reverse primers were used to clone these fragments
into pB42AD plasmid. The full-length fragments of cyclin D2, D3 were
cut from pcDNA3.0-cyclin D2, D3 by EcoRI and XhoI, and cloned
into pB42AD vector. The full-length eIF3k without the stop codon
was cloned into pcDNA3.1/Myc-His()) C vector with primer 6 (50-AC-
ACTCGAGATGGCGATGTTTGAGCAG-30, XhoI site underlined)
and primer 7 (50-TGGAATTCTCTGGGAGGAGGCCATGAT-30,
EcoRI site underlined). Tomake cyclinD3 siRNAplasmid, we designed
two complementary oligonucleotides targeted to the cyclin D3 gene
CCND3: CD3iF (50-GATCCCCGATGCTGGCTTACTGGATG-
TTCAAGAGACATCCAGTAAGCCAGCATCTTTTTGGAAA-30)
and CD3iR (50-AGCTTTTCCAAAAAGATGCTGGCTTACTGGA-
TGTCTCTTGAACATCCAGTAAGCCAGCATCGGG-30). The two
complementary oligonucleotides were then synthesized, annealed, and
ligated into pSUPERIOR vector by BglII/HindIII site. All the plas-
mids produced by PCR were conﬁrmed by sequencing.
2.6. In vitro binding analysis
Cyclins D1, D2, D3, glutathione S-transferase (GST), GST-CDK 4
and GST-eIF3k were [35S] methioninelabeled in vitro with the TNT
coupled reticulocyte lysate system (Promega) at 30 C for 90 min ac-
cording to the user manual. Twenty percent of these samples were
removed for direct analysis in an SDS–polyacrylamide gel, and the
remainders were incubated with glutathione-Sepharose beads in pro-
tein binding buﬀer (20 mM Tris, pH 7.5, 50 mM NaCl, 10% glycerol,
10 mM NaF, 1% Nonidet P-40, 1 mM NaVO4, 10 lg/ml aprotinin, 10
lg/ml leupeptin, and 1 mM PMSF) at 4 C for 2 h with constant
mixing. The beads were then washed three times with the same buﬀer
and the bound proteins were subjected to 12% SDS–PAGE analysis.
The gel was then dried and autoradiographed.
2.7. In vivo interaction assay
Forty eight hours posttransfection, cells were washed three times
with ice cold PBS and solubilized with lysis buﬀer (50 mM Tris HCl
(pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM
EGTA, 15 mM MgCl2, 60 mM b-glycerophosphate, 0.1 mM Sodium
orthovanadate, 0.1 mM NaF, 0.1 mM benzamide, 10 lg/ml aprotinin,
10 g/ml leupeptin, and 1 mM PMSF). Detergent insoluble materials
were removed by centrifugation at 12 000 rpm for 15 min at 4 C. Ten
percent of these samples were removed for direct analysis in an SDS–
polyacrylamide gel, and the remainders were incubated with the mouse
monoclonal anti-Myc antibody at 4 C for 2 h. Pre-equilibrated pro-
tein-G agarose beads (Roche) were then added, and collected by cen-
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with the lysis buﬀer. The bound proteins were eluted by boiling in SDS
sample buﬀer and resolved on a 12% SDS–PAGE gel. The proteins
were transferred onto a PVDF membrane and performed as Western
blot analysis.
2.8. Immunoﬂuorescence
HeLa cells were plated onto coverslips and were transfected with
relevant plasmids. Forty eight hours after transfection, cells were
washed with cold PBS and ﬁxed in 4% paraformaldehyde in PBS for
20 min at room temperature (RT). Cells were rinsed three times with
PBS and permeabilized with 100% methanol at )20C for 10 min.
Cells were washed with PBS again and blocked in PBS containing 5%
bovine serum albumin (BSA) and then BSA was removed. The cov-
erslips were then incubated with mouse monoclonal cyclin D3 (1:100
dilution) antibody and rabbit polyclonal anti-Myc antibody (1:200
dilution) for 2 h at RT. Coverslips were washed three times with PBS
for 5 min each and then incubated with ﬂuorescein goat anti-mouse
IgG (1:100 dilution) and goat anti-rabbit IgG-R (1:100 dilution) in
dark for 1 h at RT. Following incubation, coverslips were washed
three times with PBS and contained with Hoechst for 5 min and
washed once again in dark. The coverslips were then sealed and ex-
amined immediately in a Leica confocal microscope. Digitized images
of the ﬂuorescent-antibody-stained cells were acquired with the soft-
ware provided by Leica.
2.9. In vivo reporter synthesis assay
HeLa cells were co-transfected with 400 ng/well pRL control vector
(Promega) and pcDNA3.0-cyclin D1, D2, D3 or pSUPERIOR-cyc-
linD3 with the dose from 100 to 600 ng in six-well plates in triplicate.
The total amount of plasmid DNA was adjusted to 1.0 lg/well with
empty pcDNA3.0. After 48 h, cells were lysed in passive buﬀer and
Renilla luciferase assays were performed with the dual-luciferase re-
porter assay system (Promega) and measured using the ultra sensitive
tube luminometer (Berthold). Each experiments condition was mea-
sured in triplicate.
2.10. Quantitative real-time RT-PCR
Total RNAs were isolated with Trizol reagent from HeLa cells
transfected with pRL and pcDNA3.0-cyclin D1, D2, D3 or pSUPE-
RIOR-cyclinD3 with diﬀerent doses, 100, 300 and 600 ng, in triplicate.
Real timeRT-PCRwas performed using TaKaRa real timeRT-PCRkit
with SYBRGreen I (Roche) and ampliﬁed in BioRad iCycler according
to the manufacturer’s instructions. PCR was carried out at 95 C for 3
min, followed by 40 cycles of 95 C for 10 s and 60 C for 30 s. Melting
curves were performed to determine the speciﬁcity of the amplicon.
Each sample was completed in triplicate and a template-free negative
control (the total RNA extracted from untransfected HeLa cells) was
included. Cycle threshold (Ct) during the exponential phase of ampli-
ﬁcation was determined by real timemonitoring of ﬂuorescent emission.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a
control gene. Primers for GAPDH are 50-ATGCCAGTGAGCTTCC-
CGTTCAGC-30 and 50-GGTATCGTGGA-AGGACTCATGAC-30.
Primers for Renilla luciferase are 50-ATGATCCAGAACAAAGG-30
and 50-GAACTCGCTCAACGAACG-30. Renilla Luciferase mRNA
levels were demonstrated as the absolute number of copies normalized
against GAPDH mRNA.3. Results
3.1. Screening eIF3k as a cyclin D3-associated protein
To identify proteins that interact with cyclin D3, a screening
of human fetal liver cDNA library was performed with cyclin
D3 as bait using yeast two-hybrid system. Database searching
revealed that one of the clones encode the full-length human
eIF3k. To further conﬁrm the interaction in yeast system, the
two yeast vectors were exchanged by moving cyclin D3 from
the pLexA to pB42AD vector and eIF3k from the activation
domain (pB42AD) to the DNA-BD vector (pLexA) and the
newly constructed plasmids were co-transformed into EGY48
yeast cells. This reversed two-hybrid assay also conﬁrmed theirinteraction in yeast (Fig. 1A, 1–4). Characterization of the
other clones is in progress in our laboratory.
3.2. Mapping of the cyclin D3 region that interacted with eIF3k
To determine which domain of cyclin D3 was important for
this interaction, we searched the putative pattern of cyclin D3
in the PROSITE database. Three deﬁcient mutants were gen-
erated corresponding to diﬀerent domains of cyclin D3 (de-
signed as N1, N and C) as shown in Fig. 1B. Yeast cells were
co-transformed individually with these deﬁcient mutant con-
structs N1, N, C, the full-length constructs of cyclins D1, D2,
D3 and pLexA-eIF3k. As shown in Fig. 1A, 4–12, the C-ter-
minal part of cyclin D3 (154–292 aa) did interact with eIF3k,
while the N-terminal part of cyclin D3 lost this ability. This
suggested that the amino acids 154–292 within the C-terminal
region of cyclin D3 were responsible for eIF3k binding. In-
terestingly, no interaction was observed with the cyclin D1 and
cyclin D2 co-transformants, which implied that among D-type
cylcins, cyclin D3 might uniquely interact with eIF3k. This
prompts us to investigate their interaction pattern in following
experiments.
3.3. In vitro interactions between eIF3k and D-type cyclins
To investigate whether cyclin D3 was the unique one in the
D-type cyclins that could interact with eIF3k, GST pull-down
experiments were performed. GST-eIF3k, GST-CDK 4, GST,
cyclins D1, D2, and D3 were synthesized and isotopically la-
beled in vitro, respectively. The labeled proteins were incu-
bated in diﬀerent combinations. As shown in Fig. 2, though all
diﬀerent proteins were generated as indicated (lanes 1–5), only
cyclin D3 could bind with GST-eIF3k (lane 8) but not the
other two cyclin Ds (lanes 6,7), suggesting that this interaction
was speciﬁc in vitro, which was consistent with the result
mentioned in yeast.
3.4. Binding of cyclin D3 with eIF3k in vivo
Because we have been unsuccessful in obtaining antibodies
speciﬁc for eIF3k at present, an expression vector containing
Myc-tagged full-length eIF3k was constructed for experiments.
HeLa cells were transiently transfected with pcDNA3.1-
Myc-eIF3k or pcDNA3.1-Myc empty vector, respectively. As
shown in Fig. 3A, the endogenous cyclin D1, D2 or D3 was
detected individually by anti-cyclin D1, D2 or D3 monoclonal
antibody and the expression ofMyc-eIF3k was conﬁrmed by an
anti-Myc monoclonal antibody. The remainder cell lysates were
immunoprecipitated with anti-Myc monoclonal antibody, fol-
lowed by immunoblotting using anti-cyclinD1,D2 orD3mouse
monoclonal antibody, respectively. As shown in Fig. 3B, cyclin
D3was co-immunoprecipitatedwithMyc-eIF3k,whereas cyclin
D1 and D2 could not be detected in immunoprecipitation. This
result further veriﬁed that cyclin D3 did associate with eIF3k in
vivo and this interaction was speciﬁc.
3.5. The cellular distribution analysis of eIF3k
From Fig. 4A, we found that endogenous cyclin D3 lo-
calized both in nucleus and cytoplasm in untransfected
HeLa cells and no ﬂuorescence was seen when detected by
the Myc antibody. Immunoﬂuorescence microscopy using an
anti-Myc antibody revealed that eIF3k also localized both
in nucleus and cytoplasm in HeLa cells transfected with
Myc-eIF3k, and merging of the two images showed a yellow
Fig. 1. The yeast two-hybrid assays of D-type cyclins and deﬁcient mutants of cyclin D3 with eIF3k. (A) Individual EGY48 cells, containing relevant
plasmids (indicated as 1–12). were streaked with toothpicks onto the SD induction plates (His,Ura, Trp, Leu containing X-gal). The positive
colonies can grow on the induction plates and turn blue. (B) Mapping of cyclin D3 region required for binding to eIF3k. The top diagram illustrates
full-length eIF3k and the domains and residue numbers of deletion mutants of cyclin D3 are indicated. Columns on the right summarize whether
constructs did (+) or did not ()) interact.
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clin D3, especially in cytoplasm. To conﬁrm this observa-
tion, we performed cell fractionation and Western blotting
analysis. Again, we observed both a cytoplasmic and nu-
clear pool of eIF3k and cyclin D3 (Fig. 4C). This result was
consistent with our ﬁndings in their cellular distribution in
HeLa cells and further conﬁrmed their interaction men-
tioned above.
3.6. Upregulation of the cellular translation activity in HeLa
cells upon cyclin D3 overexpression
Since eIF3k could interact with cyclin D3, the question
arises whether cyclin D3 could play a role in regulating cel-
lular translation activity? HeLa cells were transiently co-
transfected with Renilla luciferase reporter plasmid and
pcDNA3.0-cycln D1, D2, or D3 with a dose response assay in
triplicate. The Renilla luciferase activity was then measured
and the mRNA levels were determined after 48-h transfection.
We found that Renilla luciferase synthesis was signiﬁcantlyelevated in the HeLa cells transfected with cyclin D3 in a dose
dependent manner (Fig. 5A). In contrast, Renilla luciferase
activity was not aﬀected in the HeLa cells transfected with
pcDNA3.0-cyclin D1 or D2 (Fig. 5A). To further conﬁrm the
upregulation of the cellular translation activity in HeLa cells
upon cyclin D3 overexpression, the cyclin D3 siRNA ex-
pression vector was addressed to suppress the endogenous
cyclin D3. HeLa cells were co-transfected with pSUPERIOR-
cyclinD3 under the same condition. As shown in Fig. 5A,
Renilla luciferase activity of cyclin D3 siRNA was decreased
comparing to that of cyclins D1, D2 and D3. The expression
of cyclin D1, D2, or D3 was conﬁrmed by immunoblotting in
transfected HeLa cells (Fig. 5B). Real-time RT-PCR analysis
excludes the transcriptional eﬀect of cyclins D1, D2 (data not
shown), D3 (Fig. 5C) and cyclin D3 siRNA (Fig. 5C). Taken
together, cyclin D3 upregulated the cellular protein synthesis
in vivo at the translation level, which might be achieved
through its interaction with eIF3k. This needs to be further
investigated.
Fig. 3. Association of cyclin D3 with eIF3k in vivo. (A) The expression
of cyclin D1, D2, D3 (10% input) and Myc-eIF3k (10% input) in
pcDNA3.1-Myc (control) and pcDNA3.1-Myc-eIF3k transfected
HeLa cells by Western blotting. Myc-eIF3k expression was detected
using a monoclonal antibody against the Myc-tag. The D-type cyclins
were detected using a monoclonal antibody against the cyclin D1, D2
or D3, respectively. (B) The interaction between D-cyclins and eIF3k
in pcDNA3.1-Myc(control) and pcDNA3.1-Myc-eIF3k transfected
HeLa cells. Cell lysates were immunoprecipitated (IP) with an anti-
Myc monoclonal antibody. The immunoprecipitates were immunob-
lotted (WB) with a monoclonal antibody against cyclin D1, D2 or D3,
respectively.
Fig. 2. Binding of cyclin D3 and eIF3k in vitro. Constructs were engineered as described by Section 2. In vitro translated [35S] labeled GST-eIF3k was
incubated with [35S] labeled D-type cyclins in the presence of glutathione-Sepharose beads with in vitro translated [35S] labeled GST-CDK 4 in-
cubated with cyclin D3 as a positive control, and [35S] labeled GST incubated with [35S] labeled cyclin D3 as a negative control. After incubation, the
beads were washed three times with the binding buﬀer and analyzed by autoradiography after SDS–PAGE. Lanes from left to right are 20% cyclin
D1 input (lane 1), 20% cyclin D2 input (lane 2), 20% cyclin D3 input (lane 3), 20% GST-CDK 4 input (lane 4), 20% GST-eIF3k (lane 5) input, GST-
eIF3k + cyclin D1 (lane 6), GST-eIF3k + cyclin D2 (lane 7), GST-eIF3k + cyclin D3 (lane 8), GST-CDK 4 + cyclin D3 (lane 9), and GST + cyclin
D3 (lane 10).
Fig. 4. The co-localization of cyclin D3 and eIF3k in HeLa cells. HeLa
cells were contained with Hoechst (blue) to indicate the nuclear posi-
tion. The localization of cyclin D3 (green) was detected with the mouse
monoclonal anti-cyclin D3 antibody and eIF3k (red) was with the
rabbit Myc-tag polyclonal antibody. (A) The localization of cyclin D3
in untransfected HeLa cells. (B) The co-localization of cyclin D3 and
eIF3k in HeLa cells transfected with pcDNA3.1-Myc-eIF3k. (C) The
localization of cyclin D3 and eIF3k by cell fractionation and Western
blotting. Twenty micrograms of fractionated HeLa cells lysates were
used for each lane, with mouse monoclonal anti-cyclin D3 antibody,
mouse monoclonal anti-Myc antibody and mouse monoclonal anti-
actin antibody(as a marker control) for immunoblotting.
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Fig. 5. Upregulation of the cellular translation activity in HeLa cells upon cyclin D3 overexpression. (A) The Renilla luciferase activity of cyclins D1,
D2, D3 and D3 siRNA. HeLa cells were co-transfected with 400 ng Renilla luciferase reporter plasmid and pcDNA3.0-cyclin D1, D2, D3 or D3
siRNA plasmid from 100 to 600 ng in triplicate. The total amount of plasmid DNA was adjusted to 1.0 lg/well with empty pcDNA3.0. Forty eight
hours after transfection, cells were lysed and Renilla luciferase activity was measured. (B) The expression of cyclin D1, D2 or D3 in HeLa cells
transfected individually with pcDNA3.0-cyclin D1, D2 or D3 siRNA plasmid from 100 to 600 ng. Twenty micrograms of HeLa cells lysates was used
for each lane. Actin was served as a quantitative control. (C) Quantitative real time RT-PCR analysis of the Renilla luciferase in HeLa cells. HeLa
cells were transfected with cyclin D1 (data not shown), D2 (data not shown), D3 or D3 siRNA with the doses 100, 300, and 600 ng in triplicate. Real
time RT-PCR was performed using TaKaRa real time RT-PCR kit with SYBR Green I (Roche) and ampliﬁed in BioRad iCycler according to the
manufacturer’s instructions. Renilla luciferase mRNA levels were normalized against GAPDH. Untransfected HeLa cells (HeLa())) served as a
negative control.
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In this study, we identiﬁed a p28 subunit of eIF3k as a new
interaction partner of cyclin D3. The interaction between cy-
clin D3 and eIF3k is speciﬁc through the C-terminal domain
within cyclin D3, as demonstrated by the inability of the other
two D-type cyclins to associate with eIF3k. Cyclin D3 colo-
calizes with eIF3k both in nucleus and cytoplasm. And we also
found that cyclin D3 could enhance whole cellular translation
activity in a dose-dependent way.
The three D-type cyclins exhibit homology. The human and
mouse cyclin D3 genes were originally identiﬁed by cross-
hybridizing cyclin D1 probes with a mouse phage genomic
library or a human cDNA library, respectively [23]. However,
there is more evidence that the three D-type cyclins are not
equivalent in many ways, such as the tissue-speciﬁc expression
patterns [24], diﬀerent aﬃnities to CDKs [25], diﬀerent in-
ductions by various signals in a cell lineage-speciﬁc manner
[24,26], diﬀerent phenotypes of the knockout mice [27] and
the transgenic mice [28].Our present study identiﬁed that
eIF3k interacted exclusively with cyclin D3 rather than with
cyclin D1 or cyclin D2. The peptide sequence alignment of the
three D-type cyclins revealed that they had high similarity.
(Fig. 6) One of the most important diﬀerences among cyclins
D1, D2 and D3 was at the C-terminal end of the molecule.
The eIF3k-binding site within the cyclin D3 domain was
located in residues 154–284 (Fig. 1), which corresponded to
the low homologous domain of the D-type cyclins. Therefore,
this might account for the speciﬁc interaction between cyclin
D3 and eIF3k.
Considerable attention has been paid to the role of D-type
cyclins in controlling the G1 phase progression by regulating
CDK 4 and 6 activation and Rb function. It was reported that
the overexpression of cyclin D1 or D3 using the same experi-
mental system caused a similar alteration of the cell cycle
proﬁle in asynchronous cells. Likewise, constitutive overex-
pression of cyclin D2 or D3 in 32Dcl3 myeloid cells was shown
to cause contraction of G1 without concomitant increase in the
population doubling time [29]. The phenotypic similarity of theFig. 6. Sequence alignment of D-type cyclins. The boxes in gray in-
dicate all three identical residues among the sequences of cyclin D1, D2
or D3.eﬀects of overexpression of various D cyclins does not, how-
ever, lead to the conclusion that all operate through identical
mechanisms. In our study, it was found that eIF3k did interact
with cyclin D3, and overexpression of cyclin D3 could increase
the cellular translation activity, suggesting that cyclin D3
might be an important translation regulator, and the transla-
tion regulating function of cyclin D3 to accelerate protein
synthesis did not result from the shortened G1 by cyclin D3
overexpressed, because the same phenomenon was not ob-
served by cyclin D1 or D2 (Fig. 5 ).
Sequence homology with eIF3k is found in the genomes of
Caenorhabditis elegans, Arabidopsis thaliana and Drosophila
melanogaster, and a homologous protein has been reported to
be present in wheat eIF3 [30]. No sequence similar to eIF3k
was found in S. cerevisiae and S. pombe [30], indicating that
eIF3k may play a specialized and important regulatory role in
the higher eukaryotic eIF3 complex. Considerable data sup-
port the fact that eIF3k is a true subunit of mammalian eIF3.
eIF3k, for instance, can interact directly with eIF3c, eIF3g and
eIF3j in vitro and form a stable, immunoprecipitatable com-
plex with the eIF3 core [14]. In this study, we also show by
confocal microscopy that there are both a cytoplasmic and a
nuclear pool of eIF3k. This phenomenon is uncommon. Only
several other proteins, such as eIF4E [31,32], eIF4G [33],
eIF5A [34] and eIF3f [35] can also be found in the nucleus as
well as in the cytoplasm. The data suggest that eIF3k may also
have a nuclear function, which is under investigation in our
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